Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
|ClinicalTrials.gov Identifier: NCT00993694|
Recruitment Status : Completed
First Posted : October 12, 2009
Last Update Posted : April 17, 2017
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This research study is looking at methemoglobinemia in young patients with hematologic cancer or aplastic anemia treated with dapsone.
|Condition or disease||Intervention/treatment|
|Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Methemoglobinemia Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Nonmalignant Neoplasm||Drug: chemotherapy Drug: dapsone Other: medical chart review Procedure: assessment of therapy complications|
- Define the incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years.
- Identify major risk factors for developing methemoglobinemia.
OUTLINE: Medical charts are reviewed. Of particular interest is demographic information, reasons for beginning dapsone prophylaxis, duration of dapsone prophylaxis, dapsone dosing, methemoglobin level, and treatment with methylene blue.
|Study Type :||Observational|
|Actual Enrollment :||41 participants|
|Official Title:||Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia|
|Actual Study Start Date :||January 2009|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
- Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years
- Major risk factors for developing methemoglobinemia
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00993694
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center - Cool Springs|
|Nashville, Tennessee, United States, 37064|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Principal Investigator:||Adam J. Esbenshade, MD||Vanderbilt-Ingram Cancer Center|